The 2023 Australian Down-Scheduling of Psilocybin

What changed on 1 July 2023 , and what stayed a criminal offence

Australia made headlines in February 2023 when the Therapeutic Goods Administration announced it would move psilocybin from Schedule 9 (Prohibited Substance) to Schedule 8 (Controlled Drug) for one specific, narrow use. That decision took effect on 1 July 2023. A lot of the coverage at the time was loose , breathless "Australia legalises psychedelics" headlines sitting alongside genuine legal complexity. So let's be precise about what the Poisons Standard actually says now, because the gap between the media narrative and the regulatory reality is worth understanding.

The baseline has not changed: psilocybin remains a Schedule 9 prohibited substance for virtually all purposes. Possession, use, manufacture, or supply outside the tightly defined authorised pathway is still a criminal offence under Commonwealth and state/territory law. Full stop.

What the TGA created is an exemption. Under the amended Poisons Standard, a psychiatrist who holds Authorised Prescriber status , granted by the TGA after approval from a Human Research Ethics Committee (HREC) or the TGA itself; may prescribe psilocybin as a Schedule 8 controlled drug for a single specified indication. The substance remains tightly controlled; it does not appear on the Australian Register of Therapeutic Goods (the ARTG); and patients cannot walk into a clinic and request it without this specific prescribing structure being in place.

The Authorised Prescriber pathway explained

The Authorised Prescriber scheme has existed for years as a mechanism allowing qualified practitioners to prescribe unapproved therapeutic goods outside of clinical trials. Before July 2023, psilocybin could only be accessed under the Special Access Scheme (Category B), which required individual patient applications, a significant barrier. The 2023 change streamlined this somewhat by allowing an approved psychiatrist to prescribe to a class of patients rather than seeking approval case-by-case.

But the requirements are substantial. The prescribing doctor must be a registered psychiatrist, not merely any medical practitioner. They need HREC endorsement or direct TGA approval. They must adhere to the conditions set out in the TGA's Authorised Prescriber guidelines. The psilocybin itself must come from a TGA-licensed manufacturer or importer, there is no legal provision for a patient or clinic to source it through any other channel. None.

This is why I'd argue the "Australia first country to legalise medical psychedelics" framing was always a bit of a stretch. What we have is a controlled exemption operating under strict oversight, not a broadly available medicine. It's more analogous to how Schedule 8 controlled drugs like certain opioids are managed; tightly prescribed, audited, and accountable, than it is to the cannabis access pathway most Australians are more familiar with.

Psilocybin: what it is and how it works, chemically

Psilocybin is a naturally occurring tryptamine found in certain fungal species. It is a prodrug; after ingestion the body converts it to psilocin, which is the pharmacologically active form. Psilocin binds with high affinity to serotonin receptors, particularly the 5-HT2A subtype, which is expressed densely in the prefrontal cortex. This mechanism is distinct from cannabinoids, which act on the endocannabinoid system, psilocin is not a cannabinoid and does not interact with CB1 or CB2 receptors.

The pharmacokinetics of psilocybin are reasonably well characterised in the research literature. Oral bioavailability is variable and subject to first-pass metabolism in the liver, where alkaline phosphatases dephosphorylate psilocybin to psilocin. Peak plasma concentrations of psilocin typically occur within one to two hours of oral ingestion, with effects persisting for four to six hours, according to pharmacokinetic studies published in peer-reviewed journals including work from the Beckley Foundation and Johns Hopkins University.

Honestly, the 5-HT2A agonism story is the part I find most compelling from a neuroscience standpoint; I've spent a few late evenings re-reading Robin Carhart-Harris's work on the REBUS (Relaxed Beliefs Under Psychedelics) model, which proposes that psilocin reduces the "precision weighting" of high-level predictive priors in the brain. It's a genuinely interesting theoretical framework, even if it's still a model and not settled fact. I should note: reading papers is not the same as clinical evidence for any particular use, and I say that as someone who once confidently explained to a friend how chess engines work before losing to a beginner AI in four minutes.

What the research record actually shows, and where its limits are

The TGA's decision was informed by a body of published clinical research, predominantly from institutions in the United States and United Kingdom. Randomised controlled trials, including those published in NEJM Evidence and Nature Medicine; examined psilocybin in structured clinical settings with psychological support before, during, and after administration sessions. The TGA reviewed this evidence and concluded a pathway was warranted.

But there are real limitations worth naming clearly. Sample sizes in the most-cited trials are small, often 20 to 60 participants. Follow-up periods are typically short. Most trials involve highly selected populations under controlled conditions that may not replicate in broader clinical settings. The TGA's own guidance notes that the evidence base is still developing. Researchers including those at the NICM Health Research Institute at Western Sydney University have called for larger, longer, more diverse trials. That's not me being pessimistic, it's the honest state of the science, and it's why the Authorised Prescriber pathway is narrow rather than open-ended.

Adverse effects documented in studies include anxiety, transient increases in blood pressure, confusion, and in rare cases more prolonged psychological distress. The structured clinical setting required under the AP pathway exists precisely to manage these risks.

The legal picture outside the AP pathway

This deserves its own section because it matters. Outside of a valid Authorised Prescriber arrangement, psilocybin remains Schedule 9 under the Poisons Standard; a prohibited substance. In Western Australia, where I'm based, possession of a prohibited substance carries serious criminal penalties under the Misuse of Drugs Act 1981 (WA). Other states and territories have equivalent legislation. The Australian Drug Foundation notes that penalties for possession and supply of prohibited substances vary by jurisdiction but can include significant fines and imprisonment.

There is no legal "grey zone" for recreational use, personal cultivation, or purchasing psilocybin-containing products. Retreat operators, coaches, or facilitators offering psilocybin sessions outside the AP framework are operating illegally, regardless of how they frame their services. The TGA has been explicit on this point. Anyone in Australia who has not accessed psilocybin through a TGA-approved Authorised Prescriber, which means through a qualified psychiatrist operating under HREC oversight, has not accessed it legally.

How this compares to other regulated substances

It's useful context to note that Australia's approach to psilocybin now loosely mirrors its approach to medicinal cannabis; a narrow, regulated pathway that preceded broader understanding. Medicinal cannabis became accessible via the AP and SAS pathways before it was well understood in mainstream practice; prescribing volumes grew significantly as clinical familiarity developed. Whether psilocybin follows a similar arc depends entirely on how the evidence base develops and whether the TGA broadens approvals over time. That's speculative and I won't pretend otherwise.

What's not speculative is the regulatory structure as it stands today, under the current Poisons Standard and TGA guidelines.

Sources

• Scheduling Delegate's Final Decisions, February 2023, Therapeutic Goods Administration (TGA)
• Magic Mushrooms, Australian Drug Foundation (ADF)
• Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults; NCBI / NIH
• Authorised Prescribers: Overview, Therapeutic Goods Administration (TGA)

, Daniel Okoro, Psychedelic science & law writer